Company Description
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures.
It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies.
The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019.
The company was founded in 2004 and is headquartered in Rehovot, Israel.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Yehiel Tal |
Contact Details
Address: Weizmann Science Park, 4 Oppenheimer Rehovot, 7670104 Israel | |
| Phone | 972 73 232 5600 |
| Website | collplant.com |
Stock Details
| Ticker Symbol | CLGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001631487 |
| CUSIP Number | 19516R107 |
| ISIN Number | IL0004960188 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Eran Rotem CPA | Deputy Chief Executive Officer and Chief Financial Officer |
| Yehiel Tal | Chief Executive Officer and Director |
| Oren Fahimipoor | Vice President of Operations |
| Dr. Elana Gazal | Vice President of Research and Development |
| Prof. Oded Shoseyov | Founder and Chief Scientist |
| Hadas Dreiher Horowitz | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2024 | 6-K | Report of foreign issuer |
| Aug 20, 2024 | 6-K | Report of foreign issuer |
| Aug 20, 2024 | 6-K | Report of foreign issuer |
| Aug 19, 2024 | 6-K | Report of foreign issuer |
| Jul 29, 2024 | 6-K | Report of foreign issuer |
| Jun 6, 2024 | 6-K | Report of foreign issuer |
| May 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 29, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 6-K | Report of foreign issuer |
| Apr 4, 2024 | 20-F | Annual and transition report of foreign private issuers |